Kidney Graft Function Under the Immunosuppression Strategies

Status Completed

Clinical Trial Summary

To demonstrate that cyclosporine-sparing immunosuppressions with the standard dose of Enteric-Coated Mycophenolate Sodium would preserve renal graft function after transplantation without an increase of incidences of adverse events, such as biopsy confirmed acute rejection, local or systemic infections, and bone marrow suppression.

Clinical Trial Description

This clinical investigation will be the open-label, prospective, multi-center, 1:1 randomized comparative, longitudinal, and investigator-initiated study. Patients with end-stage renal disease will be assessed for the eligibility, and then be randomized using random number table into one of two groups prior to kidney transplantation.

Immunosuppression consisted of Cyclosporine(Neoral®), Methylprednisolone OR prednisone OR deflazacort(Brand name is not designated) and Enteric-Coated Mycophenolate Sodium(Myfortic®). Basilixumab(Simulect®) will be given just prior to transplant and 4 days after transplantation. The Enteric-Coated Mycophenolate Sodium will be given orally at the dose of 720 mg BID for Group A (investigational) or 360 mg BID for Group B (comparator), starting at two days after transplantation, as shown in the figure below. Cyclosporine will be given orally at a dose of 10 mg/Kg/day starting at a day before transplantation. Within a month after transplantation, the dose of the drug will be individually adjusted with goal trough blood level between 100 ng/mL and 200 ng/mL for Group A or between 200 ng/mL and 300 ng/mL for Group B, as displayed in the table below. From a month to 2 months post-transplantation, the target blood trough levels of cyclosporine will be reduced to between 75 ng/mL and 150 ng/mL for Group A or between 150 ng/mL and 250 ng/mL for Group B. From 2 months to 4 months post-transplantation, it will be further reduced to between 50 ng/mL and 125 ng/mL for Group A or between 125 ng/mL and 200 ng/mL for Group B. After 4 months post-transplantation, it will be further reduced to between 50 ng/mL and 100 ng/mL for Group A or between 100 ng/mL and 200 ng/mL for Group B. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01817322
Study type	Interventional
Source	Samsung Medical Center
Contact
Status	Completed
Phase	Phase 4
Start date	June 2011
Completion date	August 2013

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT01155128` - Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease	Phase 4
Completed	`NCT00962000` - Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate	N/A
Completed	`NCT00560014` - Nutrient Levels Alter Transplant Outcome	N/A
Completed	`NCT03274921` - Biomarkers of Cardiovascular Complications in Chronic Kidney Disease
Completed	`NCT01964014` - Once-a-day Immunosuppression(CISECON_a_day)	Phase 4
Recruiting	`NCT01728415` - Effects of High-intensity Interval Training in Patients in Hemodialysis	N/A
Completed	`NCT01532297` - Application of Citrate Dialysate in Chronic Haemodialysis	N/A
Completed	`NCT04100551` - Relationship Between Chronic Renal Disease and Risk Stratification for Chronic Ulcer on the on the Diabetic Foot
Recruiting	`NCT04428827` - Outcome of Patients With Primary Aldosteronism
Completed	`NCT02299661` - Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease	Phase 1
Recruiting	`NCT02190318` - Residual Renal Function Preservation in Peritoneal Dialysis Patients	N/A
Terminated	`NCT01402219` - Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients	Phase 4
Not yet recruiting	`NCT04157647` - Hemadsorption During and After Cardiopulmonary Bypass to Modulate the Inflammatory Response	N/A
Completed	`NCT04897672` - 2D-speckle Tracking in Pediatric Renal Chronic Disease
Terminated	`NCT02375711` - Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient	N/A
Not yet recruiting	`NCT04940819` - A Mobile Application Based Dietary Self Management Intervention in Chinese Chronic Kidney Disease Patients	N/A
Completed	`NCT05383261` - The Impact of the Social Factors and Rehabilitation Program to Address the Implications on Kidney Failure in Hail
Completed	`NCT02834026` - Impact of the Cycle Ergometer in Muscle Strength and Pulmonary Function in Patients in Hemodialysis	N/A
Completed	`NCT02072837` - Dyslipidemia-related Risk Factors in Dialysis	N/A
Recruiting	`NCT03425708` - Effect of Hyperuricaemia on Chronic Renal Disease	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Kidney Graft Function Under the Immunosuppression Strategies — MyLowCsA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms